FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601740817> ?p ?o ?g. }

• W2601740817 endingPage "857" @default.
• W2601740817 startingPage "851" @default.
• W2601740817 abstract "The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC), the largest component of the European Randomized Study of Screening for Prostate Cancer (ERSPC), showed a smaller, nonsignificant reduction in prostate cancer-specific mortality by systematic prostate-specific antigen (PSA)-based screening compared with the overall ERSPC results. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce inflammation and also PSA elevations due to intraprostatic inflammation.To explore whether NSAID usage modifies the effects of PSA-based screening on prostate cancer incidence and mortality.A cohort of 78 165 men from the FinRSPC were linked to a comprehensive national prescription database to obtain information on NSAID reimbursements prior to screening.Prostate cancer risk and mortality were compared between the FinRSPC screening arm and the control arm among NSAID users and nonusers using an age-adjusted Cox regression model.Screening increased the detection of Gleason 6 (hazard ratio [HR] 1.59, 95% confidence interval [CI] 1.47-1.72 and HR 1.39, 95% CI 1.26-1.54) and localized prostate tumors (HR 1.25, 95% CI 1.18-1.32 and HR 1.11, 95% CI 1.03-1.20) more among baseline NSAID nonusers than among users, respectively (p for interaction <0.04 for both). This difference was observed in all three screening rounds. Detection of metastatic prostate cancer was similar in both NSAID users and nonusers. Screening decreased prostate cancer mortality among men using NSAIDs at FinRSPC randomization (HR 0.66, 95% CI 0.49-0.90) but not among nonusers (HR 0.95, 95% CI 0.81-1.12); p for interaction=0.04.Screening detected fewer well-differentiated localized tumors among NSAID users than among nonusers. This suggests that PSA screening may cause less overdiagnosis within this subgroup, whereas mortality benefit may be greater among NSAID users.Prostate cancer screening causes less overdiagnosis of well-differentiated localized prostate tumors among men who use nonsteroidal anti-inflammatory drugs." @default.
• W2601740817 created "2017-04-07" @default.
• W2601740817 creator A5011425417 @default.
• W2601740817 creator A5014952306 @default.
• W2601740817 creator A5029422912 @default.
• W2601740817 creator A5051002496 @default.
• W2601740817 creator A5061538458 @default.
• W2601740817 creator A5073365583 @default.
• W2601740817 creator A5089929040 @default.
• W2601740817 date "2018-12-01" @default.
• W2601740817 modified "2023-10-16" @default.
• W2601740817 title "Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs" @default.
• W2601740817 cites W1887861952 @default.
• W2601740817 cites W1909055669 @default.
• W2601740817 cites W2005875800 @default.
• W2601740817 cites W2030470110 @default.
• W2601740817 cites W2051890972 @default.
• W2601740817 cites W2106058419 @default.
• W2601740817 cites W2153825864 @default.
• W2601740817 cites W2159803932 @default.
• W2601740817 cites W2165559381 @default.
• W2601740817 cites W2166295609 @default.
• W2601740817 cites W2170304616 @default.
• W2601740817 cites W2049305484 @default.
• W2601740817 doi "https://doi.org/10.1016/j.euf.2017.03.005" @default.
• W2601740817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28753870" @default.
• W2601740817 hasPublicationYear "2018" @default.
• W2601740817 type Work @default.
• W2601740817 sameAs 2601740817 @default.
• W2601740817 citedByCount "4" @default.
• W2601740817 countsByYear W26017408172017 @default.
• W2601740817 countsByYear W26017408172018 @default.
• W2601740817 countsByYear W26017408172019 @default.
• W2601740817 countsByYear W26017408172023 @default.
• W2601740817 crossrefType "journal-article" @default.
• W2601740817 hasAuthorship W2601740817A5011425417 @default.
• W2601740817 hasAuthorship W2601740817A5014952306 @default.
• W2601740817 hasAuthorship W2601740817A5029422912 @default.
• W2601740817 hasAuthorship W2601740817A5051002496 @default.
• W2601740817 hasAuthorship W2601740817A5061538458 @default.
• W2601740817 hasAuthorship W2601740817A5073365583 @default.
• W2601740817 hasAuthorship W2601740817A5089929040 @default.
• W2601740817 hasConcept C120665830 @default.
• W2601740817 hasConcept C121332964 @default.
• W2601740817 hasConcept C121608353 @default.
• W2601740817 hasConcept C126322002 @default.
• W2601740817 hasConcept C126894567 @default.
• W2601740817 hasConcept C143998085 @default.
• W2601740817 hasConcept C168563851 @default.
• W2601740817 hasConcept C207103383 @default.
• W2601740817 hasConcept C2775941076 @default.
• W2601740817 hasConcept C2776235491 @default.
• W2601740817 hasConcept C2780192828 @default.
• W2601740817 hasConcept C2781406297 @default.
• W2601740817 hasConcept C29456083 @default.
• W2601740817 hasConcept C44249647 @default.
• W2601740817 hasConcept C50382708 @default.
• W2601740817 hasConcept C61511704 @default.
• W2601740817 hasConcept C71924100 @default.
• W2601740817 hasConceptScore W2601740817C120665830 @default.
• W2601740817 hasConceptScore W2601740817C121332964 @default.
• W2601740817 hasConceptScore W2601740817C121608353 @default.
• W2601740817 hasConceptScore W2601740817C126322002 @default.
• W2601740817 hasConceptScore W2601740817C126894567 @default.
• W2601740817 hasConceptScore W2601740817C143998085 @default.
• W2601740817 hasConceptScore W2601740817C168563851 @default.
• W2601740817 hasConceptScore W2601740817C207103383 @default.
• W2601740817 hasConceptScore W2601740817C2775941076 @default.
• W2601740817 hasConceptScore W2601740817C2776235491 @default.
• W2601740817 hasConceptScore W2601740817C2780192828 @default.
• W2601740817 hasConceptScore W2601740817C2781406297 @default.
• W2601740817 hasConceptScore W2601740817C29456083 @default.
• W2601740817 hasConceptScore W2601740817C44249647 @default.
• W2601740817 hasConceptScore W2601740817C50382708 @default.
• W2601740817 hasConceptScore W2601740817C61511704 @default.
• W2601740817 hasConceptScore W2601740817C71924100 @default.
• W2601740817 hasFunder F4320326147 @default.
• W2601740817 hasIssue "6" @default.
• W2601740817 hasLocation W26017408171 @default.
• W2601740817 hasLocation W26017408172 @default.
• W2601740817 hasOpenAccess W2601740817 @default.
• W2601740817 hasPrimaryLocation W26017408171 @default.
• W2601740817 hasRelatedWork W1494522156 @default.
• W2601740817 hasRelatedWork W1969572253 @default.
• W2601740817 hasRelatedWork W2029246148 @default.
• W2601740817 hasRelatedWork W2049045266 @default.
• W2601740817 hasRelatedWork W2081495044 @default.
• W2601740817 hasRelatedWork W2129795405 @default.
• W2601740817 hasRelatedWork W2141887484 @default.
• W2601740817 hasRelatedWork W2417050085 @default.
• W2601740817 hasRelatedWork W2417415279 @default.
• W2601740817 hasRelatedWork W2770076051 @default.
• W2601740817 hasVolume "4" @default.
• W2601740817 isParatext "false" @default.
• W2601740817 isRetracted "false" @default.
• W2601740817 magId "2601740817" @default.
• W2601740817 workType "article" @default.